Akcea Completes Deal That Gives It Marketing Rights to FAP Treatment Inotersen

Akcea Therapeutics has completed a deal giving it the global marketing rights to its affiliate  Ionis Pharmaceuticals’ familial amyloid polyneuropathy therapy inotersen. The deal also gives Akcea rights to a follow-up treatment known as AKCEA-TTR-L Rx, formerly known as IONIS-TTR-L Rx. Inotersen was designed for hereditary forms of FAP, which…